Biogen lays out long-awaited Alzheimer’s data in obscure journal

Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after US regulators cleared the treatment.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen and Eisai change agreements on Alzheimer's drug
For subscribers
Biogen's Alzheimer's drug loses subsidies in the US
For subscribers
Biogen slashes price of controversial Alzheimer's drug
For subscribers